---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-042144"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:18:02.803111+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# INVO raises $6M equity via share exchange with Cytovia to regain Nasdaq compliance

## Summary
- Issued 1.2M Series B Preferred shares to Cytovia for 163,637 NAYA shares valued at $6M.
- Transaction increases stockholders' equity by $6M to meet Nasdaq $2.5M minimum requirement.
- Company had Nasdaq extension through Nov 20, 2023; now expects confirmation of compliance.
- Also authorized Series A Preferred for planned $5M+ private offering related to NAYA merger.
- Series A and B Preferred convertible at $2.20 and $5.00 per share, with ownership caps of 9.99% and 19.99%.

## SEC filing metadata
- accession: 0001493152-23-042144
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-042144
- JSON: https://secwatch.observer/filing/0001493152-23-042144.json
- Plain text: https://secwatch.observer/filing/0001493152-23-042144.txt

## Key facts
- Governance Changes
  INVO Fertility, Inc.: The Company filed a Certificate of Designation for Series B Convertible Preferred Stock, establishing its rights, preferences, and privileges (effective 2023-11-20).
  - Change: charter amendment
  - Effective: 2023-11-20
  source text: On November 20, 2023, the Company filed with the Nevada Secretary of State a Certificate of Designation of Series B Convertible Preferred Stock (the “ Series B Certificate of Designation ”) which sets forth the rights, preferences, and privileges of the Series B Preferred Stock (the “ Series B Preferred ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm
- Governance Changes
  INVO Fertility, Inc.: The Company filed Certificates of Designation for two new series of preferred stock: Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, setting forth the rights, preferences, and privileges of each series (effective 2023-11-20).
  - Change: charter amendment
  - Effective: 2023-11-20
  source text: On November 20, 2023, the Company filed with the Nevada Secretary of State a Certificate of Designation of Series A Convertible Preferred Stock (the “ Series A Certificate of Designation ”) which sets forth the rights, preferences, and privileges of the Series A Preferred Stock (the “ Series A Preferred ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm
- Material Agreements
  INVO Fertility, Inc. entered into Share Exchange Agreement with Cytovia Therapeutics Holdings, Inc. (effective 2023-11-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Cytovia Therapeutics Holdings, Inc.
  - Effective: 2023-11-19
  source text: On November 19, 2023, the Company entered into a share exchange agreement (the “ Share Exchange Agreement ”) with Cytovia Therapeutics Holdings, Inc., a Delaware corporation (“ Cytovia ”) for Cytovia’s acquisition of 1,200,000 shares of the Company’s newly designated Series B Preferred Stock in exchange for 163,637 shares of common stock of NAYA held by Cytovia valued at $6,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.